Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 12/20 | 0.42 |
| ▸ | HCRTR2 | O43614 | 11/20 | 0.42 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.38 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.38 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.38 |
| ▸ | TDO2 | P48775 | 1/20 | 0.36 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.34 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.34 |
| ▸ | HTR1A | P08908 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2405425 | 0.95 | HCRTR2 (0.42) | HCRTR1HCRTR2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL2410004 | 0.90 | HCRTR2 (0.45) | HCRTR1HCRTR2TDO2HTR1A | |
| SCHEMBL2404417 | 0.90 | TDO2 (0.45) | HCRTR1HCRTR2TDO2HTR1A | |
| SCHEMBL2405315 | 0.90 | HCRTR2 (0.42) | HCRTR1HCRTR2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL2408416 | 0.88 | HCRTR2 (0.45) | HCRTR1HCRTR2MTNR1AMTNR1BHTR1A | |
| SCHEMBL2406018 | 0.88 | HCRTR2 (0.41) | HCRTR1HCRTR2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL2404990 | 0.88 | HCRTR2 (0.41) | HCRTR1HCRTR2PRKAG1PRKAA1PRKAB1 | |
| SCHEMBL2405186 | 0.87 | HCRTR2 (0.53) | HCRTR1HCRTR2MTNR1AMTNR1BHTR1A | |
| SCHEMBL2409735 | 0.87 | HCRTR2 (0.46) | HCRTR1HCRTR2TDO2MTNR1AMTNR1B | |
| SCHEMBL2407062 | 0.85 | HCRTR1 (0.39) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | claimed |
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212968-A1 | PHENETHYLAMIDE DERIVATIVES AND THEIR HETEROCYCLIC ANALOGUES | HCRTR2, HCRTR1, HRH3 | HCRTR1 2/4885HCRTR2 1/4885PRKAG1 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.